[go: up one dir, main page]

WO2006063075A2 - Recepteur de l'octopamine des hemipteres - Google Patents

Recepteur de l'octopamine des hemipteres Download PDF

Info

Publication number
WO2006063075A2
WO2006063075A2 PCT/US2005/044312 US2005044312W WO2006063075A2 WO 2006063075 A2 WO2006063075 A2 WO 2006063075A2 US 2005044312 W US2005044312 W US 2005044312W WO 2006063075 A2 WO2006063075 A2 WO 2006063075A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
seq
acid sequence
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/044312
Other languages
English (en)
Other versions
WO2006063075A3 (fr
Inventor
Cancan Huang
Ruihua Chen
Kevin Ditolvo
James Russell Eldridge
Paul Allenza
Peter Dierks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FMC Corp
Original Assignee
FMC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FMC Corp filed Critical FMC Corp
Publication of WO2006063075A2 publication Critical patent/WO2006063075A2/fr
Publication of WO2006063075A3 publication Critical patent/WO2006063075A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Definitions

  • the present invention relates to compositions that are useful in agrochemical, veterinary or pharmaceutical fields.
  • the invention relates to nucleotide sequences that encode polypeptides that are useful in the identification or development of compounds that affect octopamine receptor activity, indicating that such compounds may be useful as pesticides or as pharmaceuticals.
  • Octopamine a biogenic monoamine structurally related to noradrenaline, is a major neurotransmitter, neuromodulator and neurohormone, mediating diverse physiological processes in peripheral and central nervous system of invertebrates. Together with tyramine, octopamine is the only neuroactive non-peptide transmitter whose physiological role is restricted to invertebrates. Since its discovery in the salivary glands of Octopus (Erspamer and Boretti, Arch. Int. Pharmacodyn. 88:296- 332, 1951), octopamine has been found in neuronal, as well as in non-neuronal tissues of most invertebrate species studied.
  • Octopamine acts as a neurotransmitter for light production in firefly lantern, has excitatory modulatory functions in locust somatic and visceral muscles, and regulates carbohydrate and fatty acid metabolism (David and Coulon, Progress in Neurobiology 24: 141-185, 1985).
  • the octopamine- less fruitfly females (tbh) are sterile due to an egg retention phenotype, suggesting its modulatory role in oviductal muscle contraction (Monastirioti et al, J. Neurosci. 16:3900-391 1, 1996).
  • Octopamine is also involved in displaying submissive postures in lobsters (Livingstone et al, Science 208:76-79, 1980), escape behavior of crayfish (Glanzman and Krasne, J. Neurosci. 3:2263-2269, 1983), and feeding behaviors of blowflies (Long et al, Comp. Biochem. & Physiol-C: Comp. Pharmacol. & Toxicol. 83:201-209, 1986) and honeybees (Braun and Bicker, J. Neurophysiol. 67:588-598, 1992).
  • inactive mutants containing 15% wild-type levels of octopamine display hypoactivity (O'Dell, Heredity 70:393-399, 1993).
  • octopamine application to decapitated flies induces strong stimulation of locomotion and grooming behavior (Yellman et al, Proc. Natl. Acad. Sci. USA. 94:4131-4136, 1997).
  • crucial roles of octopamine are implicated in complex behaviors including conditioned courtship and olfactory learning (O'Dell, Behav. Genet. 24:381-388, 1994; Dudai et al, J. Comp. Physiol. A 161 :739-746, 1987).
  • Octopamine- containing neurons are widely spread out in optic lobes, antennal lobes, clusters of neurons in brain cortex, and thoracic and abdominal ganglia of Drosophila (Monastirioti et al, J. Comp. Neurol. 356:275-287, 1995.). Biochemical studies using Drosophila head homogenates reveal high affinity octopamine binding sites (Dudai and Zvi, Comp. Biochem. Physiol-C: Comp. Pharmacol. & Toxicol. 77: 145- 151, 1984) and strong potency of octopamine to stimulate adenylyl cyclase activities (Uzzan and Dudai, J. Neurochem. 38: 1542-1550, 1982).
  • octopamine modulates almost every physiological process in invertebrates.
  • Octopamine exerts its physiological actions through the octopamine receptors.
  • All octopamine receptors belong to the family of G-protein coupled receptors.
  • Four different types of octopamine receptors can be distinguished using pharmacological tools. They show different coupling to second messenger systems including activation and inhibition of adenylyl cyclase, activation of phospholipase C, and coupling to a chloride channel.
  • octopamine is a principal neuromediator in insects, its receptors have proven to be difficult to clone. To date, only a few octopamine receptors have been cloned. Two octopamine receptors, Lym oal (Gerhardt et al, MoI. Pharmacol. 51 :293-300, 1997) and Lym oa2 (Gerhardt et al, J. Biol. Chem. 272: 6201-6207, 1997), were cloned from the pond snail Lymnaea.
  • Lym oa2 While Lym oa2 is coupled to chloride channels in HEK cells, Lym oa2 can stimulate both adenylyl cyclase and phospholipase C.
  • Ap oal One octopamine receptor gene, was cloned from sea snail Aplysia. It couples selectively and positively to the cAMP/PKA pathway (Chang et al, Proc. Natl. Acad. Sci. USA 97:1829-1834, 1999).
  • Another octopamine receptor, Am oal was cloned from honeybee (Apis mellifera) brain.
  • Nanomolar concentration of octopamine induced oscillatory increases in the intracellular Ca2+ concentration (Grohman et al, J. Neurochem. 86:725-735, 2003).
  • Still another octopamine receptor (OAMB) was cloned from Drosophila mushroom bodies. Human and Drosophila cell lines expressing OAMB showed increased cAMP and intracellular Ca2+ levels after octopamine application (Han et al, J. Neurosci. 18(10):3650-3658, 1998).
  • Octopamine receptors are believed to be good targets for highly specific insecticides as they are not found in vertebrates.
  • adenylyl cyclase-coupled octopamine receptor from insects offers a tremendous opportunity to use the cloned receptor to screen for new pesticides.
  • Agonists and/or antagonists to the receptor can be used to control insects and other pests through their neurotoxic effects.
  • novel pesticides developed against this target would have a low probability of exhibiting toxicity to vertebrate species.
  • nucleotide sequences that encode polypeptides with octopamine receptor activity.
  • nucleotide sequences encode polypeptides with hemipteran octopamine receptor activity.
  • Such nucleotide sequences may be used to express amino acid sequences that are useful in the identification or development of compounds that affect octopamine receptor activity. Such compounds may be useful as pesticides or as pharmaceuticals.
  • nucleotide sequences that encode polypeptides with octopamine receptor activity, preferably hemipteran octopamine receptor activity, including mutants and fragments thereof, which will be further described below, will also be referred to herein as "nucleotide sequences of the invention”.
  • polypeptides with octopamine receptor activity preferably hemipteran octopamine receptor activity, including mutants and fragments thereof, which will be further characterized below, will also be described as "proteins of the invention," “amino acid sequences of the invention, " or “polypeptide of the invention”
  • the present invention further relates to the use of the nucleotide sequences of the invention, preferably in the form of a suitable genetic construct as described below, in the transformation of host cells or host organisms, for example for the expression of the amino acid sequences of the invention and to such genetic constructs and host cells.
  • Another aspect of the invention relates to methods for the identification or development of compounds that can modulate and/or inhibit the biological activity of the amino acid sequences of the invention, in which one or more of the above mentioned nucleotide sequences, amino acid sequences, genetic constructs, host cells or host organisms are used. Such methods, which will usually be in the form of an assay or screen, will also be further described below.
  • a further aspect of the invention relates to compounds that can modulate the biological activity of, or that can otherwise interact with, an amino acid sequence of the invention, either in vitro or preferably (also) in vivo.
  • the invention also relates to compositions that contain such compounds, and to the use of such compounds in the preparation of these compositions and the control of pests.
  • Figure 1 is data showing Octopamine stimulates cAMP production in a dose dependent manner in HEK-293 cells expressing two isoforms of aphid octopamine receptors. Definitions
  • nucleic acids of the present invention will be referred to herein as “nucleic acids of the invention”. Also, where appropriate in the context of the further description of the invention below, the terms “nucleotide sequence of the invention” and “nucleic acid of the invention” may be considered essentially equivalent and essentially interchangeable.
  • nucleic acid or amino acid sequence is considered to be "(in) essentially isolated (form)" - for example, from its native biological source - when it has been separated from at least one other nucleic acid molecule and/or sequence with which it is usually associated.
  • a protein or polypeptide of the invention is considered to be "(in) essentially isolated (form)” - for example, from its native biological source - when it has been effectively separated from other polypeptide molecules with which it is normally associated.
  • a nucleic acid or polypeptide of the invention is considered “essentially isolated” when it has been purified at least 2-fold, in particular at least 10-fold, more in particular at least 100-fold, and up to 1000-fold or more.
  • a novel octopamine receptor was cloned for cotton aphid named CA oal .
  • This receptor is coupled to the cAMP pathway. When expressed in HEK293 cells, it causes increase in the cAMP concentration upon application of octopamine.
  • Stable mammalian expression cell lines have been established and are utilized to screen for novel pesticides.
  • nucleic acid preferably in essentially isolated form, which nucleic acid comprises a nucleotide sequence of the invention, and in particular the nucleotide sequence of SEQ ID NO: 1 AND SEQ ID NO: 3, and mutants and fragments thereof.
  • the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, preferably SEQ NO: 1 was derived or isolated from the Aphis gossypii organism, in the manner as further described in the Examples below.
  • the present invention also relates to polypeptides of the invention, and in particular those comprising SEQ ID NO: 2 or SEQ ID NO: 4, and mutants and fragments thereof.
  • nucleotide sequences of the invention when in the form of a nucleic acid, may be DNA or RNA, and may be single stranded or double stranded.
  • the nucleotide sequences of the invention may be genomic DNA, cDNA or synthetic DNA (such as DNA with a codon usage that has been specifically adapted for expression in the intended host cell or host organism, which may for instance be designed using suitable computer programs such as the BackTranslate analysis tool in Vector NTI (InforMax, Inc., Bethesda, MD).
  • the nucleotide sequences of the invention may contain intron sequences, and also generally comprises different splice variants.
  • Yet another embodiment relates to a double stranded RNA molecule directed against a nucleotide sequence of the invention (one strand of which will usually comprise at least part of a nucleotide sequence of the invention).
  • double stranded RNA molecules have particular utility in RNA interference studies of gene function (Zamore et al, Cell 101 :25-33 (2000)).
  • the invention also relates to genetic constructs that can be used to provide such double stranded RNA molecules (e.g. by suitable expression in a host cell or host organism, or for example in a bacterial strain such as E.col ⁇ ). For such constructs, reference is made to Maniatis et al., Molecular Cloning, a Laboratory Manual (Cold Spring Harbor Press, 1989).
  • nucleotide sequence of the invention also comprises: parts or fragments of the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, preferably SEQ ID NO: 1; - (natural or synthetic) mutants, variants, alleles, analogs, orthologs (herein below collectively referred to as "mutants") of the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, as further described below as further described below as well as any nucleotide sequence that encodes a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2, or SEQID NO:4 and fragments thereof and DNA sequences that detectably hybridize to such DNA sequences or their complementary strands under conditions of moderate or high stringency; .
  • the invention also comprises different splice variants of the above nucleotide sequences.
  • the nucleotide sequence of the invention is a fragment of a nucleic acid molecule that encodes an octopamine receptor.
  • a nucleotide sequence of the invention will have a length of at least 500 nucleotides, preferably at least 1,000 nucleotides, more preferably at least 1,200 nucleotides; and up to a length of at most 3,500 nucleotides, preferably at most 3,000 nucleotides, more preferably at most, 2,240 nucleotides.
  • parts or fragments of the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, preferably SEQ ID NO: 1 ; or a part or fragment of a (natural or synthetic) mutant thereof include, but are not limited to, 5' or 3' truncated nucleotide sequences, or sequences with an introduced in frame start codon or stop codon. Also, two or more such parts or fragments of one or more nucleotide sequences of the invention may be suitably combined (e.g. ligated in frame) to provide a further nucleotide sequence of the invention.
  • such parts or fragments comprise at least one continuous stretch of at least 100 nucleotides, preferably at least 250 nucleotides, more preferably at least 500 nucleotides, even more preferably more than 1,000 nucleotides, of the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, preferably SEQ ID NO: 1.
  • the mutant is such that it encodes the nucleotide sequence of SEQ ID NO: 1 or a part or fragment thereof. In another specific embodiment, the mutant is such that it encodes the nucleotide sequence of SEQ ID NO: 3 or a part or fragment thereof
  • any mutants as described herein will have one or more, and preferably all, of the structural characteristics or conserved features referred to below for the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 3.
  • any mutants, parts or fragments as described herein may be such that they at least encode the active or catalytic site of the corresponding amino acid sequence of the invention and a binding domain of the corresponding amino acid sequence of the invention.
  • any mutants, parts or fragments as described herein will preferably have a degree of "sequence identity", at the nucleotide level, with the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, preferably SEQ ID NO: 1, of at least 75%, preferably at least 80%, more preferably at least 85%, and in particular more than 90%, and up to 95% or more.
  • any mutants, parts or fragments of the nucleotide sequence of the invention will be such that they encode an amino acid sequence which has a degree of "sequence identity", at the amino acid level, with the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, preferably SEQ ID NO: 2, of at least 55%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% and up to 95% or more, in which the percentage of "sequence identity" is calculated as described below.
  • the percentage of "sequence identity" between a given nucleotide sequence and the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3 may be calculated by dividing the number of nucleotides in the given nucleotide sequence that are identical to the nucleotide at the corresponding position in the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3 by the total number of nucleotides in the given nucleotide sequence and multiplying by 100%, in which each deletion, insertion, substitution or addition of a nucleotide - compared to the sequence of SEQ ID NO: 1 or SEQ ID NO: 3 - is considered as a difference at a single nucleotide position.
  • the preferred computer program for performing global sequence alignments and determining sequence identity is ClustalW (Higgins et al., Nucleic Acids Research 22:4673-4680,1994), which is publicly available for a variety of computer platforms.
  • any mutants, parts or fragments as described herein will encode proteins or polypeptides having biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO: 1 and SEQ ID NO: 3, preferably SEQ ID NO: 1, i.e. to a degree of at least 55%, preferably at least 75%, and up to 90%, as measured by standard assay techniques as described below.
  • Any mutants, parts or fragments as described herein are preferably such that they are capable of hybridizing with the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, preferably SEQ ID NO: 1, i.e. under conditions of "moderate stringency", and preferably under conditions of "high stringency".
  • nucleotide sequence of the invention (as described above) with one or more further nucleotide sequence(s), including but not limited to one or more coding sequences, non-coding sequences or regulatory sequences.
  • the one or more further nucleotide sequences are operably connected (as described below) to the nucleotide sequence of the invention (for example so that, when the further nucleotide sequence is a coding sequence, the nucleotide fusion encodes a protein fusion as described below).
  • the invention relates to an antisense molecule against a nucleotide sequence of the invention.
  • a nucleic acid preferably in essentially isolated form, can be used to express an amino acid sequence of the invention, for example, the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
  • the nucleotide sequences of some embodiments of the invention encode proteins that have biological activity or ligand binding properties of octopamine receptor from insects of the order Hemiptera which include aphids, leafhoppers, whiteflies, scales and true bugs that have mouthparts adapted to piercing and sucking.
  • the nucleic acids of the invention may also be in the form of a genetic construct, again as further described below.
  • Genetic constructs of the invention will generally comprise at least one nucleotide sequence of the invention, optionally linked to one or more elements of genetic constructs known per se, as described below.
  • Such genetic constructs may be DNA or RNA, and are preferably double- stranded DNA.
  • the constructs may also be in a form suitable for transformation of the intended host cell or host organism, in a form suitable for integration into the genomic DNA of the intended host cell or in a form suitable independent replication, maintenance and inheritance in the intended host organism.
  • the genetic construct may be in the form of a vector, such as for example a plasmid, cosmid, a yeast artificial chromosome ("YAC”), a viral vector or transposon.
  • the vector may be an expression vector, i.e.
  • An expression vector comprising a nucleotide sequence of the invention is also referred to herein as a recombinant expression vector.
  • These constructs will also be referred to herein as "genetic constructs of the invention”.
  • such a construct a recombinant expression vector which will comprise: a) the nucleotide sequence of the invention; operably connected to: b) one or more regulatory elements, such as a promoter and optionally a suitable terminator; and optionally also: c) one or more further elements of genetic constructs known per se; in which the terms "regulatory element”, “promoter”, “terminator”, “further elements” and “operably connected” have the meanings indicated herein below.
  • the genetic construct(s) of the invention may generally contain one or more suitable regulatory elements (such as a suitable promoter(s), enhancer(s), or terminator(s)), 3'- or 5'- untranslated region(s) ("UTR") sequences, leader sequences, selection markers, expression markers or reporter genes, or elements that may facilitate or increase (the efficiency of) transformation or integration.
  • suitable regulatory elements such as a suitable promoter(s), enhancer(s), or terminator(s)
  • UTR 3'- or 5'- untranslated region(s)
  • TTR 3'- or 5'- untranslated region(s)
  • suitable elements for such genetic constructs will be clear to the skilled person, and may for instance depend upon the type of construct used, the intended host cell or host organism; the manner in which the nucleotide sequences of the invention of interest are to be expressed (e.g. via constitutive, transient or inducible expression); and the transformation technique to be used.
  • the one or more further elements are "operably linked' to the nucleotide sequence(s) of the invention or to each other, by which is generally meant that they are in a functional relationship with each other.
  • a promoter is considered “operably linked” to a coding sequence if said promoter is able to initiate or otherwise control or regulate the transcription or the expression of a coding sequence (in which said coding sequence should be understood as being "under the control of said promoter)
  • nucleotide sequences when operably linked, they will be in the same orientation and usually also in the same reading frame. They will usually also be essentially contiguous, although this may also not be required.
  • the optional further elements of the genetic construct(s) used in the invention are such that they are capable of providing their intended biological function in the intended host cell or host organism.
  • a promoter, enhancer or terminator should be "operable" in the intended host cell or host organism, by which is meant that (for example) said promoter should be capable of initiating or otherwise controlling or regulating the transcription or the expression of a nucleotide sequence - e.g. a coding sequence - to which it is operably linked (as defined above).
  • Such a promoter may be a constitutive promoter or an inducible promoter, and may also be such that it (only) provides for expression in a specific stage of development of the host cell or host organism, or such that it (only) provides for expression in a specific cell, tissue, organ or part of a multicellular host organism.
  • Some particularly preferred promoters include, but are not limited to, constitutive promoters, such as cytomegalovirus (“CMV”), Rous sarcoma virus (“RSV”), simian virus-40 (“SV40”), for example, pSVL SV40 Late Promoter Expression Vector (Pharmacia Biotech Inc., Piscataway, NJ), or herpes simplex virus (“HSV”) for expression in mammalian cells or insect constitutive promoters such as the immediate early baculovirus promoter described by Jarvis et al. (Methods in Molecular BiologyVol. 39 Baculovirus Expression Protocols, ed. C.
  • a selection marker should be such that it allows - i.e. under appropriate selection conditions - host cells or host organisms that have been (successfully) transformed with the nucleotide sequence of the invention to be distinguished from host cells or organisms that have not been (successfully) transformed.
  • Some preferred, but non-limiting examples of such markers are genes that provide resistance against antibiotics (such as geneticin or G-418 (GIBCO- BRL, Grand Island, NY), kanamycin or ampicillin), genes that provide for temperature resistance, or genes that allow the host cell or host organism to be maintained in the absence of certain factors, compounds or (food) components in the medium that are essential for survival of the non-transformed cells or organisms.
  • a leader sequence should be such that - in the intended host cell or host organism - it allows for the desired post-translational modifications or such that it directs the transcribed mRNA to a desired part or organelle of a cell such as a signal peptide.
  • a leader sequence may also allow for secretion of the expression product from said cell.
  • the leader sequence may be any pro-, pre-, or prepro- sequence operable in the host cell or host organism, including, but not limited to, picornavirus leaders, potyvirus leaders, a human immunoglobulin heavy-chain binding protein ("BiP"), a tobacco mosaic virus leader (“TMV”), and a maize chlorotic mottle virus leader (“MCMV”).
  • An expression marker or reporter gene should be such that - in the host cell or host organism - it allows for detection of the expression of (a gene or nucleotide sequence present on) the genetic construct.
  • An expression marker may optionally also allow for the localization of the expressed product, e.g. in a specific part or organelle of a cell or in (a) specific cell(s), tissue(s), organ(s) or part(s) of a multicellular organism.
  • Such reporter genes may also be expressed as a protein fusion with the amino acid sequence of the invention.
  • Some preferred, but non-limiting examples include fluorescent proteins, such as GFP, antibody recognition proteins, for example, V5 epitope or poly Histidine available in vectors and antibodies supplied by Invitrogen, or purification affinity handles such as polyhistidine which allows for purification on nickel columns or dihydrofolate reductase which allows for purification on methotrexate column, or markers which allow for selection of cells expressing the gene such as the E. coli beta-galactosidase gene.
  • fluorescent proteins such as GFP
  • antibody recognition proteins for example, V5 epitope or poly Histidine available in vectors and antibodies supplied by Invitrogen
  • purification affinity handles such as polyhistidine which allows for purification on nickel columns or dihydrofolate reductase which allows for purification on methotrexate column, or markers which allow for selection of cells expressing the gene such as the E. coli beta-galactosidase gene.
  • promoters selection markers, leader sequences, expression markers and further elements that may be present or used in the genetic constructs of the invention - such as terminators, transcriptional or translational enhancers or integration factors - reference is made to the general handbooks such as Sambrook et al. and Ausubel et al. mentioned above, to W.B. Wood et al., "The nematode Caenorhabditis elegans", Cold Spring Harbor
  • Another embodiment of the invention relates to a host cell or host organism that has been transformed or contains with a nucleotide sequence, with a nucleic acid or with a genetic construct of the invention.
  • the invention also relates to a host cell or host organism that expresses, or (at least) is capable of expressing (e.g. under suitable conditions), an amino acid sequence of the invention.
  • host cells or host organisms will also be referred to herein as "host cells or host organisms of the invention”.
  • the host cell may be any suitable (fungal, prokaryotic or eukaryotic) cell or cell line, for example: - a bacterial strain, including but not limited to strains of E. coli, Bacillus, Streptomyces or Pseudomonas; a fungal cell, including but not limited to cells from species of Aspergillus or Trichoderma; a yeast cell, including but not limited to cells from species of Kluyveromyces or Saccharomyces; an amphibian cell or cell line, such as Xenopus oocytes.
  • a suitable (fungal, prokaryotic or eukaryotic) cell or cell line for example: - a bacterial strain, including but not limited to strains of E. coli, Bacillus, Streptomyces or Pseudomonas; a fungal cell, including but not limited to cells from species of Aspergillus or Trichoderma; a yeast cell, including but not limited to cells from species of Kluyveromy
  • the host cell may be an insect-derived cell or cell line, such as: cells or cell lines derived from Hemipteran, including, but not limited to, Spodoptera SF9 and Sf21 cells and cells or cell lines derived from Aphis; cells or cell lines derived from Drosophila, such as Schneider and Kc cells; and cells or cell lines derived from a pest species of interest (as mentioned below), such as from Aphis gossypii.
  • insect-derived cell or cell line such as: cells or cell lines derived from Hemipteran, including, but not limited to, Spodoptera SF9 and Sf21 cells and cells or cell lines derived from Aphis; cells or cell lines derived from Drosophila, such as Schneider and Kc cells; and cells or cell lines derived from a pest species of interest (as mentioned below), such as from Aphis gossypii.
  • the host cell may also be a mammalian cell or cell line, including but not limited to CHO- and BHK-cells and human cells or cell lines such as HEK, HeLa and COS.
  • the host organism may be any suitable multicellular (vertebrate or invertebrate) organism, including but not limited to: a nematode, including but not limited to nematodes from the genus Caenorhabditis, such as C. elegans, an insect, including but not limited to species of Aphis, Drosophila, Heliothis, or a specific pest species of interest (such as those mentioned above); - other well known model organisms, such as zebrafish; a mammal such as a rat or mouse;
  • nucleotide sequence of the invention when expressed in a multicellular organism, it may be expressed throughout the entire organism, or only in one or more specific cells, tissues, organs or parts thereof, for example by expression under the control of a promoter that is specific for said cell(s), tissue(s), organ(s) or part(s).
  • the nucleotide sequence may also be expressed during only a specific stage of development or life cycle of the host cell or host organism, again for example by expression under the control of a promoter that is specific for said stage of development or life cycle. Also, as already mentioned above, said expression may be constitutive, transient or inducible.
  • these host cells or host organisms are such that they express, or are (at least) capable of expressing (e.g. under suitable conditions), an amino acid sequence of the invention (and in case of a host organism: in at least one cell, part, tissue or organ thereof).
  • the invention also includes further generations, progeny and offspring of the host cell or host organism of the invention, which may for instance be obtained by cell division or by sexual or asexual reproduction.
  • the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, preferably SEQ ID NO: 2 may be isolated from the species mentioned above, using any technique(s) for protein isolation and purification known to one skilled in the art.
  • amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, preferably SEQ ID NO: 2 may be obtained by suitable expression of a suitable nucleotide sequence - such as the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3 or a suitable mutant thereof - in an appropriate host cell or host organism, as further described below.
  • a suitable nucleotide sequence - such as the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3 or a suitable mutant thereof - in an appropriate host cell or host organism, as further described below.
  • the invention relates to a protein or polypeptide, preferably in (essentially) isolated form, said protein or polypeptide comprising an amino acid sequence of the invention (as defined above), in particular the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, more particularly preferred the amino acid sequence of SEQ ID NO 2.
  • amino acid sequence of the invention also comprises: - parts or fragments of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4;
  • analogs (natural or synthetic) mutants, variants, alleles, analogs, orthologs (herein below collectively referred to as "analogs") of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4; - parts or fragments of such analogs; fusions of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 (or a part or fragment thereof) with at least one further amino acid residue or sequence; fusions of the amino acid sequence of an analog (or a part or fragment thereof) with at least one further amino acid residue or sequence; in which such mutants, parts, fragments or fusions are preferably as further described below.
  • amino acid sequence of the invention also comprises “immature” forms of the above-mentioned amino acid sequences, such as a pre-, pro- or prepro- forms or fusions with suitable leader sequences.
  • amino acid sequences of the invention may have been subjected to post-translational processing or be suitably glycosylated, depending upon the host cell or host organism used to express or produce said amino acid sequence; or may be otherwise modified (e.g. by chemical techniques known per se in the art).
  • an amino acid sequence of the invention has a length of at least 100 amino acids, preferably at least 250 amino acids, more preferably at least 300 amino acids; and up to a length of at most 1,000 amino acids, preferably at most 750 amino acids, more preferably at most 600 amino acids.
  • any such parts or fragments will be such that they comprise at least one continuous stretch of at least 5 amino acids, preferably at least 10 amino acids, more preferably at least 20 amino acids, even more preferably more than 30 amino acids, of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.
  • any parts or fragments as described herein are such that they (at least) comprise the active or catalytic site of the corresponding amino acid sequence of the invention or a binding domain of the corresponding amino acid sequence of the invention.
  • such parts or fragments may find particular use in assay- and screening techniques (as generally described below) and (when said part or fragment is provided in crystalline form) in X-ray crystallography.
  • any mutants as described herein will have one or more, and preferably all, of the structural characteristics or conserved features referred to below for the sequences of SEQ ID NO: 2 or SEQ ID NO: 4, preferably SEQ ID NO: 2.
  • any analogs, parts or fragments as described herein will be such that they have a degree of "sequence identity", at the amino acid level, with the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, preferably SEQ ID NO: 2, of at least 55%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, and in particular more than 90% and up to 95 % or more.
  • the percentage of "sequence identity" between a given amino acid sequence and the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 may be calculated by dividing the number of amino acid residues in the given amino acid sequence that are identical to the amino acid residue at the corresponding position in the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 by the total number of amino acid residues in the given amino acid sequence and multiplying by 100%, in which each deletion, insertion, substitution or addition of an amino acid residue - compared to the sequence of SEQ ID NO: 2 or SEQ ID NO: 4 - is considered as a difference at a single amino acid (position).
  • the preferred method of performing pairwise global sequence alignments fur such calculations is with the program ClustalW.
  • any analogs, parts or fragments as described herein will have a biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO: 2 and SEQ ID NO: 4, preferably SEQ ID NO: 2, i.e. to a degree of at least 10%, preferably at least 50% more preferably at least 75%, and up to 90%, as measured by standard assay techniques as described below.
  • fusions may be obtained by suitable expression of a suitable nucleotide sequence of the invention - such as a suitable fusion of a nucleotide sequence of the invention with one or more further coding sequences - in an appropriate host cell or host organism, as further described below.
  • a suitable nucleotide sequence of the invention such as a suitable fusion of a nucleotide sequence of the invention with one or more further coding sequences - in an appropriate host cell or host organism, as further described below.
  • fusions may comprise an amino acid sequence of the invention fused with a reporter protein such as glutathione S- transferase ("GST”), green fluorescent protein (“GFP”), luciferase or another fluorescent protein moiety.
  • GST glutathione S- transferase
  • GFP green fluorescent protein
  • luciferase luciferase or another fluorescent protein moiety.
  • the fusion partner may be an amino acid sequence or residue that may be used in purification of the expressed amino acid sequence, for example using affinity techniques directed against said sequence or residue. Thereafter, said sequence or residue may be removed (e.g. by chemical or enzymatical cleavage) to provide the nucleotide sequence of the invention (for this purpose, the sequence or residue may optionally be linked to the amino acid sequence of the invention via a cleavable linker sequence).
  • Some preferred, but non-limiting examples of such residues are multiple histidine residues and glutatione residues.
  • any such fusion will have a biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO: 2 and SEQ ID NO: 4, preferably SEQ ID NO: 2, i.e. to a degree of at least 10%, preferably at least 50 % more preferably at least 75%, and up to 90%, as measured by standard assay techniques as described below.
  • the functional protein is a G protein coupled receptor.
  • a G coupled receptor By analogy to other octopamine receptor, it is likely that the functional protein is a G protein coupled receptor. In particular, a G coupled receptor.
  • the present invention has shown activity as an octopamine receptor from insects of the order Hemiptera, which are aphids, leafhoppers, whiteflies, scales and true bugs that have mouthparts adapted to piercing and sucking.
  • activity of Gs-coupled receptor can be determined by measuring cAMP content. It is preferred that when performing test assays using test compounds, the test compounds be prepared as serial dilutions such that multiple test assays are performed with the same compound at different concentrations.
  • assays optionally employ positive controls such as compounds known to have a particular biological activity.
  • the positive control may be an antibody specific for the polypeptide of the invention.
  • assays optionally employ negative controls such as compounds known not to have a particular biological activity.
  • kits can be provided to allow for such assays to be performed. Kits can include containers containing some or all of the reagents needed to perform the assay, samples of a polypeptide of the invention, a nucleic acid of the invention, a genetic construct of the invention or a host cell of the invention.
  • nucleic acid probe that is capable of hybridizing with a nucleotide sequence of the invention under conditions of moderate stringency, preferably under conditions of high stringency, and in particular under stringent conditions (all as described above).
  • nucleotide probes may for instance be used for detecting or isolating a nucleotide sequence of the invention or as a primer for amplifying a nucleotide sequence of the invention; all using techniques known per se, for which reference is again made to the general handbooks such as Sambrook et al. and Ausubel et al., mentioned above.
  • such a nucleotide probe when to be used for detecting or isolating another nucleotide sequence of the invention, such a nucleotide probe will usually have a length of between 15 and 100 nucleotides, and preferably between 20 and 80 nucleotides. When used as a primer for amplification, such a nucleotide probe will have a length of between 25 and 75 nucleotides, and preferably between 20 and 40 nucleotides.
  • probes can be designed by the skilled person starting from a nucleotide sequence or amino acid sequence of the invention - and in particular the sequence of SEQ ID NO: 1 or SEQ ID NO: 2 - optionally using a suitable computer algorithm.
  • probes may be degenerate probes.
  • Probes and primers preferably have sequences that include unique sequences.
  • a unique sequence is a sequence that is not found on other DNA molecules. The presence of unique sequences ensures that the probe or primer will not cross hybridize to identical sequences found on other genes.
  • One skilled in the art can readily determine if a probe or primer contains unique sequences by first designing the probe or primer and then comparing the sequences thereof with sequences in databases of known nucleic acid sequences. Such comparisons are routinely performed by those skilled in the art.
  • the invention relates to methods for preparing mutants and genetic constructs of the nucleotide sequences of the present invention.
  • Natural mutants of the nucleotide sequences of the present invention may be obtained in a manner essentially analogous to the method described in the Examples, or alternatively by: construction of a DNA library from the species of interest in an appropriate expression vector system, followed by direct expression of the mutant sequence; - construction of a DNA library from the species of interest in an appropriate expression vector system, followed by screening of said library with a probe of the invention (as described below) or with a nucleotide sequence of the invention; isolation of mRNA that encodes the mutant sequence from the species of interest, followed by cDNA synthesis using reverse transcriptase; or by any other suitable method(s) or technique(s) known per se, for which reference is for instance made to the standard handbooks, such as Sambrook et al., "Molecular Cloning: A Laboratory Manual" (2nd.ed.), VoIs.
  • the genetic constructs of the invention may generally be provided by suitably linking the nucleotide sequence(s) of the invention to the one or more further elements described above, for example using the techniques described in the general handbooks such as Sambrook et al. and Ausubel et al., mentioned above. Often, the genetic constructs of the invention will be obtained by inserting a nucleotide sequence of the invention in a suitable (expression) vector known per se.
  • suitable expression vectors include: vectors for expression in mammalian cells: pSVL SV40 (Pharmacia), pMAMneo (Clontech), pcDNA3 (Invitrogen), pMClneo (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593), pBPV-1 (8-2) (ATCC 37110), pdBPV-MMTneo (342-12) (ATCC 37224), pRSVgpt (ATCC37199), pRSVneo (ATCC37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460) and 1ZD35 (ATCC 37565); vectors for expression in bacterial cells: pET vectors (Novagen), pGEX vectors (Pharmacia) and pQE vectors (Qiagen); vectors for expression in yeast or other fungal cells:
  • the invention relates to methods for transforming a host cell or a host organism with a nucleotide sequence, with a nucleic acid or with a genetic construct of the invention.
  • the invention also relates to the use of a nucleotide sequence, of a nucleic acid or of a genetic construct of the invention transforming a host cell or a host organism.
  • the expression of a nucleotide sequence of the invention in a host cell or host organism may be reduced, compared to the original (e.g. native) host cell or host organism. This may for instance be achieved in a transient manner using antisense or RNA-interference techniques well known in the art, or in a constitutive manner using random, site specific or chemical mutagenesis of the nucleotide sequence of the invention.
  • Suitable transformation techniques will be clear to the skilled person and may depend on the intended host cell or host organism and the genetic construct to be used. Some preferred, but non-limiting examples of suitable techniques include ballistic transformation, (micro-)injection, transfection (e.g. using suitable transposons), electroporation and lipofection. For these and other suitable techniques, reference is again made to the handbooks and patent applications mentioned above.
  • a step for detecting and selecting those host cells or host organisms that have been successfully transformed with the nucleotide sequence or genetic construct of the invention may be performed. This may for instance be a selection step based on a selectable marker present in the genetic construct of the invention or a step involving the detection of the amino acid sequence of the invention, e.g. using specific antibodies.
  • the transformed host cell which may be in the form or a stable cell line
  • host organisms which may be in the form of a stable mutant line or strain
  • the invention relates to methods for producing an amino acid sequence of the invention.
  • a transformed host cell or transformed host organism may generally be kept, maintained or cultured under conditions such that the (desired) amino acid sequence of the invention is expressed or produced. Suitable conditions will be clear to the skilled person and will usually depend upon the host cell or host organism used, as well as on the regulatory elements that control the expression of the (relevant) nucleotide sequence of the invention. Again, reference is made to the handbooks and patent applications mentioned above in the paragraphs on the genetic constructs of the invention.
  • suitable conditions may include the use of a suitable medium, the presence of a suitable source of food or suitable nutrients, the use of a suitable temperature, and optionally the presence of a suitable inducing factor or compound (e.g. when the nucleotide sequences of the invention are under the control of an inducible promoter); all of which may be selected by the skilled person.
  • a suitable inducing factor or compound e.g. when the nucleotide sequences of the invention are under the control of an inducible promoter
  • the amino acid sequences of the invention may be expressed in a constitutive manner, in a transient manner, or only when suitably induced.
  • amino acid sequence of the invention may (first) be generated in an immature form (as mentioned above), which may then be subjected to post-translational modification, depending on the host cell or host organism used.
  • amino acid sequence of the invention may be glycosylated, again depending on the host cell or host organism used.
  • amino acid sequences of the invention may then be isolated from the host cell or host organism or from the medium in which said host cell or host organism was cultivated, using protein isolation and purification techniques known per se, such as (preparative) chromatography and electrophoresis techniques, differential precipitation techniques, affinity techniques (e.g. using a specific, cleavable amino acid sequence fused with the amino acid sequence of the invention) and preparative immunological techniques (i.e. using antibodies against the amino acid sequence to be isolated).
  • protein isolation and purification techniques known per se, such as (preparative) chromatography and electrophoresis techniques, differential precipitation techniques, affinity techniques (e.g. using a specific, cleavable amino acid sequence fused with the amino acid sequence of the invention) and preparative immunological techniques (i.e. using antibodies against the amino acid sequence to be isolated).
  • affinity techniques e.g. using a specific, cleavable amino acid sequence fused with the amino acid sequence of the invention
  • preparative immunological techniques i.e. using
  • the present invention relates to antibodies, for example monoclonal and polyclonal antibodies, that are generated specifically against amino acid sequences of the present invention, preferably SEQ ID NO: 2, or an analog, variant, allele, ortholog, part, fragment or epitope thereof or SEQ ID NO: 4, or an analog, variant, allele, ortholog, part, fragment or epitope thereof.
  • the antibody does not cross reactive with other octopamine receptor polypeptides.
  • Such antibodies which form a further aspect of the invention, may be generated in a manner known per se, for example as described in GB-A-2 357 768, USA 5,693,492, WO 95/32734, WO 96/23882, WO 98/02456, WO 98/41633 and WO 98/49306.
  • such methods will involve as immunizing a immunocompetent host with the pertinent amino acid sequence of the invention or an immieuxic part thereof (such as a specific epitope), in amount(s) and according to a regimen such that antibodies against said amino acid sequence are raised, and than harvesting the antibodies thus generated, e.g. from blood or serum derived from said host.
  • polyclonal antibodies can be obtained by immunizing a suitable host such as a goat, rabbit, sheep, rat, pig or mouse with (an epitope of) an amino acid sequence of the invention, optionally with the use of an immunogenic carrier (such as bovine serum albumin or keyhole limpet hemocyanin) or an adjuvant such as Freund's, saponin, aluminium hydroxide or a similar mineral gel, or keyhole limpet hemocyanin or a similar surface active substance.
  • an immunogenic carrier such as bovine serum albumin or keyhole limpet hemocyanin
  • an adjuvant such as Freund's, saponin, aluminium hydroxide or a similar mineral gel, or keyhole limpet hemocyanin or a similar surface active substance.
  • the antibodies can be isolated from blood or serum taken from the immunized animal in a manner known per se, which optionally may involve a step of screening for an antibody with desired properties (i.e.
  • Monoclonal antibodies may for example be produced using continuous cell lines in culture, including hybridoma-based and similar techniques, again essentially as described in the above cited references. Accordingly, cells and cell lines that produce monoclonal antibodies against an amino acid sequence of the invention form a further aspect of the invention, as do methods for producing antibodies against amino acid sequences of the invention, which methods may generally involve cultivating such a cell and isolating the antibodies from the culture or medium, again using techniques known per se.
  • Fab-fragments against the amino acid sequences of the invention may be obtained by digestion of an antibody with pepsin or another protease, reducing disulfide-linkages and treatment with papain and a reducing agent, respectively.
  • Fab-expression libraries may for instance be obtained by the method of Huse et al., 1989, Science 245:1275-1281.
  • the amino acid sequence of the invention may also be used to identify or develop compounds or other factors that can modulate the (biological) activity of, or that can otherwise interact with, the amino acid sequences of the invention, and such uses form further aspects of the invention.
  • the amino acid sequence of the invention will serve as a target for interaction with such a compound or factor.
  • a modulator is a compound or factor that can enhance, inhibit or reduce or otherwise alter, influence or affect (collectively referred to as "modulation") a functional property of a biological activity or process (for example, the biological activity of an amino acid sequence of the invention).
  • modulation a functional property of a biological activity or process
  • octopamine receptor activity can be measured using standard assay techniques such as cAMP assay.
  • test compounds can be prepared as serial dilutions such that multiple test assays are performed with the same compound at different concentrations.
  • assays optionally employ positive controls such as compounds known to have a particular biological activity.
  • the positive control may be an antibody specific for the polypeptide of the invention.
  • assays optionally employ negative controls such as compounds known not to have a particular biological activity.
  • kits can be provided to allow for such assays to be performed. Kits can include containers containing some or all of the reagents needed to perform the assay, samples of a polypeptide of the invention, a nucleic acid of the invention, a genetic construct of the invention or a host cell of the invention.
  • amino acid sequence of the invention may serve as a target for modulation in vitro (e.g. as part of an assay or screen) or for modulation in vivo (e.g. for modulation by a compound or factor that is known to modulate the target, which compound or factor may for example be used as an active compound for agrochemical, veterinary or pharmaceutical use).
  • amino acid sequences, host cells or host organisms of the invention may be used as part of an assay or screen that may be used to identify or develop modulators of the amino acid sequence of the invention, such as a primary screen (e.g. a screen used to identify modulators of the target from a set or library of test chemicals with unknown activity with respect to the target) or a secondary assay (e.g. an assay used for validating hits from a primary screen or used in optimizing hit molecules, e.g. as part of hits-to-leads chemistry).
  • a primary screen e.g. a screen used to identify modulators of the target from a set or library of test chemicals with unknown activity with respect to the target
  • a secondary assay e.g. an assay used for validating hits from a primary screen or used in optimizing hit molecules, e.g. as part of hits-to-leads chemistry.
  • an assay or screen may be configured as an in vitro assay or screen.
  • Such an assay or screen may also be configured as a cell-based assay or screen, in which a host cell of the invention is contacted with or exposed to a test chemical, upon which at least one biological response by the host cell is measured.
  • such an assay or screen may also be configured as an whole animal screen, in which a host organism of the invention is contacted with or exposed to a test chemical, upon which at least one biological response (such as a phenotypical, behavioral or physiological change, including but not limited to paralysis or death) by the host organism is measured.
  • a biological response such as a phenotypical, behavioral or physiological change, including but not limited to paralysis or death
  • the assays and screens described above will comprise at least one step in which the test chemical is contacted with the target (or with a host cell or host organism that expresses the target), and in particular in such a way that a signal is generated that is representative for the modulation of the target by the test chemical. In a further step, said signal may then be detected.
  • the invention relates to a method for generating a signal that is representative for the interaction of an amino acid sequence of the invention with a test chemical, said method at least comprising the steps of: a) contacting the amino acid sequence of the invention, or a host cell or host organism containing or expressing an amino acid sequence, with said test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said amino acid sequence; and optionally b) detecting the signal that may thus be generated.
  • the invention in another aspect, relates to a method for identifying modulators and/or inhibitors of an amino acid sequence of the invention (e.g. from a set or library of test chemicals), said method at least comprising the steps of: a) contacting the amino acid sequence of the invention, or a host cell or host organism containing or expressing an amino acid sequence, with a test chemical, in such a way that a signal may be generated that is representative for the interaction between said test chemical and said the target; and optionally b) detecting the signal that may thus be generated, said signal identifying the modulator and/or inhibitor of said amino acid sequence.
  • the present invention provides methods of identifying a modulator and/or inhibitor of octopamine receptor activity.
  • the octopamine receptor protein used in the methods has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, a mutant thereof, a fragment thereof, SEQ ID NO: 4, a mutant thereof, and a fragment thereof, preferably SEQ ID NO: 2.
  • the nucleic acid sequence that encodes the octopamine receptor is SEQ ID NO: 1 a fragment thereof, SEQ ID NO: 3, or a fragment thereof, preferably SEQ ID NO: 1.
  • a test chemical may be part of a set or library of compounds, which may be a diverse set or library or a focused set or library, as will be clear to the skilled person.
  • the libraries that may be used for such screening can be prepared using combinatorial chemical processes known in the art or conventional means for chemical synthesis.
  • the assays and screens of the invention may be carried out at medium throughput to high throughput, for example in an automated fashion using suitable robotics.
  • the method of the invention may be carried out by contacting the target with the test compound in a well of a multi-well plate, such as a standard 24, 96, 384, 1536 or 3456 well plate.
  • the target or host cell or host organism will be contacted with only a single test compound.
  • a test chemical may be used per se as a modulator and/or inhibitor of the relevant amino acid sequence of the invention, preferably, an amino acid sequence of SEQ ID NO: 2, a mutant thereof, a fragment thereof, SEQ ID NO: 4, a mutant thereof, and a fragment thereof, more preferably SEQ ID NO: 2 (e.g. as an active substance for agrochemical, veterinary or pharmaceutical use), or it may optionally be further optimized for final use, e.g. to improve properties such as solubility, adsorption, bio-availability, toxicity, stability, persistence, environmental impact, etc.
  • nucleotide sequences preferably SEQ ID NO: 1 or SEQ ID NO: 3, more preferably SEQ ID NO: 1, amino acid sequences, host cells or host organisms and methods of the invention may find further use in such optimization methodology, for example as (part of) secondary assays.
  • the invention is not particularly limited to any specific manner or mechanism in or via which the modulator and/or inhibitor (e.g. the test chemical, compound or factor) modulates, inhibits, or interacts with, the target (in vivo or in vitro).
  • the modulator and/or inhibitor may be an agonist, an antagonist, an inverse agonist, a partial agonist, a competitive inhibitor, a noncompetitive inhibitor, a cofactor, an allosteric inhibitor or other allosteric factor for the target, or may be a compound or factor that enhances or reduces binding of target to another biological component associated with its (biological) activity, such as another protein or polypeptide, a receptor, or a part of organelle of a cell.
  • the modulator and/or inhibitor may bind with the target (at the active site, at an allosteric site, at a binding domain or at another site on the target, e.g. covalently or via hydrogen bonding), block and/or inhibit the active site of the target (in a reversible, irreversible or competitive manner), block and/or inhibit a binding domain of the target (in a reversible, irreversible or competitive manner), or influence or change the conformation of the target.
  • test chemical, modulator and/or inhibitor may for instance be: an analog of a known substrate of the target; - an oligopeptide, e.g. comprising between 2 and 20, preferably between 3 and 15 amino acid residues; an antisense or double stranded RNA molecule; a protein, polypeptide; a cofactor or an analog of a cofactor.
  • the test chemical, modulator and/or inhibitor may also be a reference compound or factor, which may be a compound that is known to modulate, inhibit or otherwise interact with the target (e.g. a known substrate or inhibitor for the target) or a compound or factor that is generally known to modulate, inhibit or otherwise interact with other members from the general class to which the target belongs (e.g. a known substrate or inhibitor of said class).
  • the test chemical, modulator and/or inhibitor is a small molecule, by which is meant a molecular entity with a molecular weight of less than 1500, preferably less than 1000.
  • This may for example be an organic, inorganic or organometallic molecule, which may also be in the form or a suitable salt, such as a water-soluble salt.
  • suitable salt such as a water-soluble salt.
  • small molecule also covers complexes, chelates and similar molecular entities, as long as their (total) molecular weight is in the range indicated above.
  • the compounds or factors that have been identified or developed as modulators and/or inhibitors of the amino acid sequences of the invention may be useful as active substances in the agrochemical, veterinary or pharmaceutical fields, for example in the preparation of agrochemical, veterinary or pharmaceutical compositions, and both such modulators as well as compositions containing them further aspects of the invention.
  • the modulators and/or inhibitors of the invention may be used as an insecticide, nematicide, molluscide, helminticide, acaricide or other types of pesticides or biocides, e.g. to prevent or control
  • the modulators and/or inhibitors may for example be used as a crop protection agent, as a pesticide for household use, or as an agent to prevent or treat damage caused by harmful organisms (e.g. for the protection of seed, wood or stored crops or fruits).
  • the modulators and/or inhibitors of the invention are used as insecticides.
  • one or more modulators and/or inhibitors of the invention may be suitably combined with one or more agronomically acceptable carriers, adjuvants or diluents - and optionally also with one or more further compounds known per se with activity as (for example) a plant protection agent (to broaden the spectrum of action and optionally to provide a synergistic effect), herbicide, fertilizer or plant growth regulator - to provide a formulation suitable for the intended final use.
  • a plant protection agent to broaden the spectrum of action and optionally to provide a synergistic effect
  • herbicide herbicide
  • fertilizer or plant growth regulator - to provide a formulation suitable for the intended final use.
  • Such a formulation may for example be in the form of a solution, emulsion, dispersion, concentrate, aerosol, spray, powder, flowable, dust, granule, pellet, fumigation candle, bait or other suitable solid, semi-solid or liquid formulation, and may optionally also contain suitable solvents, emulsifiers, stabilizers, surfactants, antifoam agents, wetting agents, spreading agents, sticking agents, attractants or (for a bait) food components.
  • compositions may generally contain one or more modulators and/or inhibitors of the invention in a suitable amount, which generally may be between 0.1 and 99 %, and in particular between 10 and 50 %, by weight of the total composition.
  • modulators and/or inhibitors and compositions of the invention may be particularly useful as insecticides, for example to combat or control undesired or harmful insects (both adult and immature forms, such as larvae) from following orders: - Coleoptera, such as Pissodes strobi, Diabrotica undecimpunctata howardi, and Leptinotarsa decemlineata;
  • Diptera such as Rhagoletis pomonella, Mayetiola destructor, and Liriomyza huidobrensis;
  • Hymenoptera such as Neodiprion taedae tsugcte, Camponotus pennsylvanicus, and Solenopsis wagneri;
  • Hemiptera such as Pseudatomoscelis seriatus, Lygus lineolaris (Palisot de Beauvois), Acrosternum hilare, and Aphis gossypii Homoptera; and
  • the modulators, inhibitors, or other compositions of the invention may be directly applied to and/or contacted with these organisms or their environment in an amount suitable to control (e.g. kill or paralyze) the organism.
  • This amount may be readily determined by the skilled person (e.g. by testing the compound on the species to be controlled) and will usually be in the region of between particular between 10 and 500 g ⁇ a, in particular between 100 and 250 g/ha.
  • modulators, inhibitors, or compositions of the invention may also be applied systemically (e.g. to the habitat of the organism to be controlled or to the soil), and may also be applied to the plant, seed, fruit etc. to be protected, again in suitable amounts, which can be determined by the skilled person.
  • the modulators and/or inhibitors of the invention may also be incorporated - e.g. as additives - in other compositions known per se, for example to replace other pesticidal compounds normally used in such compositions.
  • the modulators and/or inhibitors and compositions of the invention may be used in the fields of agrochemical, veterinary or human health to prevent or treat infection or damage or discomfort caused by parasitic organisms, and in particular by parasitic arthropods, nematodes and helminths such as: ectoparasitic arthropods such as ticks, mites, fleas, lice, stable flies, horn flies, S blowflies and other biting or sucking ectoparasites; endoparasites organisms such as helminths; and also to prevent or treat diseases that are caused or transferred by such parasites.
  • parasitic arthropods, nematodes and helminths such as: ectoparasitic arthropods such as ticks, mites, fleas, lice, stable flies, horn flies, S blowflies and other biting or sucking ectoparasites; endoparasites organisms such as helminths
  • the modulators and/or inhibitors of the invention may for example be formulated as a tablet, an oral solution or emulsion, an injectable 0 solution or emulsion, a lotion, an aerosol, a spray, a powder, a dip or a concentrate.
  • the modulators, inhibitors, and compositions of the invention may also be used for the prevention or treatment of diseases or disorders in which the amino acid sequence of the invention may be involved as a target.
  • the modulators and/or inhibitors of the 5 invention may be formulated with one or more additives, carriers or diluents acceptable for pharmaceutical or veterinary use, which will be clear to the skilled person.
  • the invention relates to the use of a modulator and/or inhibitor of the invention in the preparation of a composition for 0 agrochemical, veterinary or pharmaceutical use, as described hereinabove.
  • the invention relates to the use of the modulators, inhibitors and compositions of the invention in controlling harmful organisms and in preventing infestation or damage caused by harmful organisms, again as described above.
  • Example 1 Cloning of Aphis gossypii octopamine receptor 1. Isolation of poly(A + ) RNA. Cotton aphids (mixed life stage) were collected from cotton plants and placed in ice-chilled glass centrifuge tubes which had been cleaned and baked for 6 hours at 18O 0 C prior to use. Aliquots of approximately 0.4 gram of cotton aphids were used for isolation of poly(A + ) RNA. Diethyl pyrocarbonate (DEPC)-treated water was made by incubating DEPC
  • RNA isolation was done using QuickPrep mRNA Purification kit
  • a cDNA libraries enriched for full-length clones was constructed by Invitrogen Corporation (Carlsbad, CA) from poly(A)-containing RNA purified from mixed life stage Aphis gossypii described above. This library was constructed in plasmid vector pCMV-SPORT6.1 and transformed into E. coli strain DHlOB (TonA). The library was stored without further amplification as a glycerol culture at -8O 0 C. A portion of the cDNA library was amplified, normalized and arrayed in 384 well plates by Invitrogen Corporation.
  • the arrayed clones were subjected to automated sequence analysis using vector primers that flanked the 5' and 3' termini of the cloned cDNA (Genome Therapeutics, Waltham, MA).
  • the sequence reads were trimmed for quality and vector contamination, assembled into contigs and installed into a BLAST-compatible database.
  • Access to the Basic Local Alignment Sequence Tool (BLAST) suite of search tools and instructions for the use of these tools and the construction of BLAST-compatible databases can be obtained from the National Center for Biotechnology Information at the National Institutes for Health (Bethesda, MD).
  • An octopamine receptor partial cDNA sequence was identified in FMC proprietary Aphis gossypii EST (Expressed Sequencing Tag) library through sequence comparison. Primers for RecA cloning (table 1) were designed based on the EST sequence information.
  • cDNAs corresponding to Aphis gossypii octopamine receptor partial cDNA sequence were isolated from the cotton aphid cDNA library by RecA- mediated gene enrichment using the RecActiveTM Gene Enrichment Kit and protocol from Active Motif (Carlsbad, CA). Briefly, a biotinylated probe was synthesized from the cDNA fragment by a PCR reaction containing the appropriate primers A and D (see Table 1) and biotin-dNTP mix from RecActiveTM.
  • the biotinylated probe was then gel purified and used to clone full length Cotton Aphid cDNAs from the non-normalized Cotton Aphid cDNA library by recA-mediated gene selection, as implemented in the RecActiveTM Gene Enrichment Kit. PCR using the appropriate primers B and C were used to screen isolated clones. Resulting clones of the correct size for a full-length insert for octopamine receptors were sequenced to confirm completeness. Two clones were identified differing in one amino acid: SEQ ID NOl and SEQ ID NO 3.
  • Example 2 Expression of Aphis gossypii octopamine receptor Octopamine receptor was expressed in HEK-293 cells.
  • PCR was used to introduce the Kozak consensus sequence to octopamine receptors (SEQ ID NO 1 and SEQ ID NO 3).
  • the resulting Kozak- containing full length gene was cloned into pcDNA3.1(+) vector by restriction digestion.
  • the recombinant vector was then transfected into HEK-293 cells with lipofectamine.
  • the positive cell clones were obtained through G418 selection for receptor activity assays.
  • Example 3 Octopamine receptor activity functional assay The receptor activity was determined by cAMP production in HEK-293 cells. Concentration of cAMP in HEK cells was measured using HTRF method per manufacturer's instruction (CIS bio international). As shown in the Figure 1, HEK- 293 cells expressing aphid octopamine receptor gene increase the production of cAMP upon octopamine stimulation, in a concentration-dependent manner, indicating the receptor is a Gs-coupled receptor, as expected, (note: lower fluorescent reading indicating higher cAMP concentration). The pEC50 of the receptor is determined to be approximately 6.3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouvelles séquences d'acide nucléique codant pour un récepteur de l'octopamine, ainsi que des expressions recombinantes et des cellules hôtes contenant ce récepteur. L'invention concerne également un récepteur de l'octopamine, des cellules hôtes exprimant un récepteur de l'octopamine, des procédés permettant de produire ce récepteur de l'octopamine, et des anticorps spécifiques de ces récepteurs de l'octopamine. L'invention concerne en outre des procédés permettant d'identifier des modulateurs et/ou des inhibiteurs du récepteur de l'octopamine.
PCT/US2005/044312 2004-12-06 2005-12-06 Recepteur de l'octopamine des hemipteres Ceased WO2006063075A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63347204P 2004-12-06 2004-12-06
US60/633,472 2004-12-06

Publications (2)

Publication Number Publication Date
WO2006063075A2 true WO2006063075A2 (fr) 2006-06-15
WO2006063075A3 WO2006063075A3 (fr) 2006-12-28

Family

ID=36578533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044312 Ceased WO2006063075A2 (fr) 2004-12-06 2005-12-06 Recepteur de l'octopamine des hemipteres

Country Status (1)

Country Link
WO (1) WO2006063075A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008054A3 (fr) * 2012-07-02 2015-08-20 Pioneer Hi-Bred International, Inc. Nouvelles protéines insecticides et leurs procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344776A (en) * 1991-03-28 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding an insect octopamine receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008054A3 (fr) * 2012-07-02 2015-08-20 Pioneer Hi-Bred International, Inc. Nouvelles protéines insecticides et leurs procédés d'utilisation

Also Published As

Publication number Publication date
WO2006063075A3 (fr) 2006-12-28

Similar Documents

Publication Publication Date Title
Balfanz et al. A family of octapamine receptors that specifically induce cyclic AMP production or Ca2+ release in Drosophila melanogaster
US20050136511A1 (en) GABA B receptors
EP2067787A1 (fr) Procédé pour le contrôle de populations d'insectes
Xia et al. A new family of insect muscarinic acetylcholine receptors
US7622269B2 (en) Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
Chen et al. Functional and pharmacological characterization of a β-adrenergic-like octopamine receptor from the silkworm Bombyx mori
US20040213771A1 (en) Targets and screens for agents useful in controlling parasitic nematodes
WO2007121512A1 (fr) Récepteurs olfactifs d'insectes
WO2007056043A2 (fr) Utilisation de canaux potassiques pour identifier des composes qui ont un effet insecticide
WO2006063075A2 (fr) Recepteur de l'octopamine des hemipteres
US6887661B1 (en) Recombinant bHLH-PAS/JHR polypeptide and its use to screen potential insecticides
AU2008200389A1 (en) Insect olfactory receptors and ligands therefor
WO2006057917A2 (fr) Recepteur 5ht1 hemipteran
Smith et al. Are Caenorhabditis elegans receptors useful targets for drug discovery: pharmacological comparison of tyramine receptors with high identity from C. elegans (TYRA-2) and Brugia malayi (Bm4)
AU2002360654A1 (en) Insect g protein-coupled receptor genes and uses thereof
WO2006101830A2 (fr) Canal ionique active par un ligand d'hemipteran glutamate
US20070077592A1 (en) Hemipteran glutamate decarboxylase
EP1578376A2 (fr) Kinases dites polo-like d'hemipteres
AU2005226676A1 (en) Compositions and methods for controlling insects related to the octopamine receptor
US20060281900A1 (en) Lepidoptera voltage-gated calcium channels
Lismont Using BRET-based G protein biosensors to unravel the G protein mediated pathways in insects
WO2006073587A2 (fr) Récepteur de la sérotonine 5-hydroxytryptamine 7 d'hémiptère
JP2001299369A (ja) 昆虫由来のペプチドの受容体
EP1575917A2 (fr) Recepteur muscarinique d'hemipteres
US20040211865A1 (en) Sterol carrier protein-2 from the mosquito, Aedes aegypti

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05853274

Country of ref document: EP

Kind code of ref document: A2